Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Two new metabolites of sulfinpyrazone in the rabbit: a possible cause of the prolonged in vivo effect.

Literature DB >> 524326

Two new metabolites of sulfinpyrazone in the rabbit: a possible cause of the prolonged in vivo effect.

A K Pedersen, P Jakobsen.

Abstract

Entities: Chemical Species

Mesh：

Substances：
Sulfinpyrazone

Year: 1979 PMID： 524326 DOI： 10.1016/0049-3848(79)90233-0

Source DB: PubMed Journal: Thromb Res ISSN： 0049-3848 Impact factor: 3.944

Keyword Cloud
Cited

× No keyword cloud information.

11 in total

1. Endogenous prostacyclin biosynthesis and platelet function during selective inhibition of thromboxane synthase in man.

Authors: G A FitzGerald; A R Brash; J A Oates; A K Pedersen
Journal: J Clin Invest Date: 1983-10 Impact factor: 14.808

Review 2. Clinical pharmacokinetics and potentially important drug interactions of sulphinpyrazone.

Authors: A K Pedersen; P Jakobsen; J P Kampmann; J M Hansen
Journal: Clin Pharmacokinet Date: 1982 Jan-Feb Impact factor: 6.447

3. Enhanced drug metabolism after sulfinpyrazone treatment in patients aged 50 to 60 years.

Authors: E Walter; C Staiger; J de Vries; E Weber; W Bitzer; M Degott; K Jüngling
Journal: Klin Wochenschr Date: 1982-11-15

4. Effect of single and multiple doses of sulphinpyrazone on antipyrine metabolism and urinary excretion of 6-beta-hydroxycortisol.

Authors: C Staiger; F Schlicht; E Walter; U Gundert-Remy; R Hildebrandt; J de Vries; N S Wang; J Harenberg; E Weber
Journal: Eur J Clin Pharmacol Date: 1983 Impact factor: 2.953

10. Pharmacokinetics and reversible biotransformation of sulfinpyrazone and its metabolites in rabbits. I. Single-dose study.

Authors: W A Ritschel
Journal: Pharm Res Date: 1986-06 Impact factor: 4.200

Two new metabolites of sulfinpyrazone in the rabbit: a possible cause of the prolonged in vivo effect.

1. Endogenous prostacyclin biosynthesis and platelet function during selective inhibition of thromboxane synthase in man.

Review 2. Clinical pharmacokinetics and potentially important drug interactions of sulphinpyrazone.

3. Enhanced drug metabolism after sulfinpyrazone treatment in patients aged 50 to 60 years.

4. Effect of single and multiple doses of sulphinpyrazone on antipyrine metabolism and urinary excretion of 6-beta-hydroxycortisol.

5. Sulphinpyrazone metabolism during long-term therapy.

6. Determination of sulfinpyrazone and four metabolites in plasma and urine by high pressure liquid chromatography.

7. Pharmacokinetics of single doses of sulphinpyrazone and its major metabolites in plasma and urine.

Review 8. Sulfinpyrazone: a review of its pharmacological properties and therapeutic use.

9. Pharmacokinetics of sulphinpyrazone and its major metabolites after a single dose and during chronic treatment.

10. Pharmacokinetics and reversible biotransformation of sulfinpyrazone and its metabolites in rabbits. I. Single-dose study.